معرفی
Professor Philip Hogg serves as Chair in Translational Cancer Research for Sydney Catalyst at the NH&MRC Clinical Trials Centre, University of Sydney. He is a leading researcher in the field of protein biochemistry with focus on disulfide bond regulation in disease processes, particularly in cancer and thrombosis. His work bridges basic science and clinical applications through his affiliation with the Charles Perkins Centre and The Centre for Drug Discovery Innovation.
- University of Sydney, Faculty of Medicine and Health
- NH&MRC Clinical Trials Centre
- Sydney Catalyst - Translational Cancer Research Centre
- Charles Perkins Centre
- Centre for Drug Discovery Innovation
Professor Hogg's research centers on the role of allosteric disulfide bonds in protein function, particularly how they regulate processes in thrombosis and cancer. His laboratory investigates protein disulfide isomerases and their role in blood coagulation, as well as developing novel cancer therapeutics targeting mitochondrial function. A significant portion of his recent work focuses on imaging cell death in tumors using radiopharmaceuticals like CDI, which binds to Hsp90 in dying cells.
Analysis of Professor Hogg's recent publications reveals a strong focus on the intersection of biochemistry and hematology, with particular emphasis on how mechanical forces and redox states regulate protein function in thrombosis. His work on von Willebrand factor, platelet function, and protein disulfide isomerases has provided fundamental insights into blood coagulation mechanisms. Simultaneously, his cancer research has advanced the development of mitochondrial-targeted therapeutics like PENAO and imaging techniques for monitoring tumor response to treatment.
Professor Hogg has successfully mentored numerous PhD students and postdoctoral researchers, with current student Naveen Eugene Louis working on mechanomedicine against von Willebrand factor. His research program is supported by substantial funding from NHMRC, ARC, Cancer Institute NSW, and other organizations, totaling millions of dollars in active grants focused on cancer therapeutics, thrombosis mechanisms, and molecular imaging.
His laboratory operates at the cutting edge of translational research, with several projects moving from basic discovery toward clinical application. The development of CDI for imaging tumor cell death represents a prime example of this translational approach, now progressing to clinical trials. His work on PENAO and related compounds demonstrates a sustained commitment to developing novel cancer therapeutics based on mitochondrial targeting.